Effects of antiepileptic drugs on reproductive endocrine function, sexual function and sperm parameters in Chinese Han men with epilepsy.
The effects of the antiepileptic drugs sodium valproate (VPA) and levetiracetam (LEV) on reproductive endocrine function, sexual function, and spermatozoa were explored, together with their possible etiological mechanisms, in Chinese Han men with epilepsy. Following VPA treatment (n=32), luteinizing hormone and follicle-stimulating hormone levels were significantly lower than in controls (n=30). The bioactive testosterone/luteinizing hormone ratio and the prolactin level were significantly elevated in the VPA treatment group. There were no significant differences in these hormones between the LEV treatment (n=20) and control groups. The rates of sperm morphologic abnormality (head, body, and tail) were significantly higher in the VPA treatment group than the control group but did not differ significantly between the LEV treatment and control groups. The sperm motility rate was significantly lower in the VPA treatment group (grade A sperm motility rate <25%, grade A+B sperm motility rate <50%) than in controls, as well as in the LEV treatment group (grade A sperm motility rate <25%). Patients in the VPA and LEV treatment groups had lower scores on questions 1, 2 and 3 of a simplified International Index of Erectile Function Scale than controls, but no significant difference on questions 4 or 5. The total International Index of Erectile Function Scale scores were significantly lower in the VPA and LEV treatment groups. We conclude that treatment with VPA adversely affects reproductive endocrine function, sperm parameters and sexual function to varying degrees in Chinese men with epilepsy.
Department of Neurology, Yangzhou University, Jiangsu, Yangzhou, China.
Xu
X
Xiaotian
Zhang
Z
Hengzhong
Xu
X
Yao
Zhao
Z
Zhipan
Xu
X
Daoliang
Wu
W
Yumei
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D044466:Asian People; D004827:Epilepsy / Q000188:drug therapy*; D007172:Erectile Dysfunction / Q000139:chemically induced*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007248:Infertility, Male / Q000139:chemically induced*; D000077287:Levetiracetam; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013094:Spermatozoa / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
D000927:Anticonvulsants; D013739:Testosterone; D000077287:Levetiracetam; D014635:Valproic Acid; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D010889:Piracetam
Epilepsy; Levetiracetam; Sex hormone; Sexual function; Sodium valproate; Sperm